|
|
Post by dannykatz on Aug 31, 2015 11:59:40 GMT -5
|
|
|
|
Post by notamnkdmillionaire on Aug 31, 2015 12:01:17 GMT -5
The story, from other sources, has been posted twice so far and no, Afrezza isn't involved yet. Maybe somewhere down the line but right now, no.
|
|
|
|
Post by kc on Aug 31, 2015 12:03:11 GMT -5
But you just never know if it ties into this MannKind inhaler?
mnkd.proboards.com/thread/3166/mannkind-inhalation-simulation-system-patented Very nice device. Perhaps it will lead to be able to dial in and set whatever dosage the user needs. Also being able to keep track to a phone or computer that dosage used or for the CGM to tel the device how much insulin to dose to the user. This might have been Al's slip of the tongue last year.
This very well might be the elimination of the Insulin pump as you know it today. You have to wonder if this is a collaboration of MannKind, Sanofi and Medtronic. I know many have asked the question about all insulin being taken with a Technosphere device? that is above my knowledge of Diabetes and physiology
www.freepatentsonline.com/y2015/0196724.html
1. An apparatus comprising: a first acoustic sensor in communication with a first breath-powered dry powder inhaler, the first sensor configured to monitor an inhalation maneuver of a patient and transmit a signal corresponding to the inhalation maneuver; a processing device comprising a microprocessor and a storage medium having an algorithm stored therein, the device configured to receive the signal from the first sensor and processing the signal using the algorithm to generate a data set that is analyzed, stored, printed, transmitted, and/or displayed; a controller that receives the data set and in turn controls a motor that is attached to a calibrated syringe pump that upon actuation by the controller generates a pressure differential in a second breath-powered dry powder inhaler that is attached to an anatomically correct artificial airway; a display in communication with the processing device and configured to graphically display both the inhalation maneuver and data collected as a result of the pressure differential, wherein the pressure differential is modeled after the inhalation maneuver.
2. The apparatus of claim 1, wherein the first sensor is located within the first inhaler or configured to attach to the first inhaler.
3. The apparatus of claim 1, wherein the first inhaler and the second inhaler are breath-powered dry powder inhalers each comprising a sensor and a microprocessor built within the respective inhalers or provided in a device attachable to the inhalers.
4. The apparatus of claim 1, wherein the first sensor is a microphone.
5. The apparatus of claim 1, wherein the second inhaler comprises a cartridge comprising a dry powder for pulmonary delivery.
6. The apparatus of claim 5, wherein the cartridge comprises a dry powder comprising diketopiperazine microparticles.
7. The apparatus of claim 5, wherein the dry powder comprises at least one active ingredient.
8. The apparatus of claim 7, wherein the at least one active ingredient comprises insulin, GLP-1, growth hormone, sumatriptan, parathyroid hormone, or analogs thereof.
9. The apparatus of claim 6, wherein the dry powder comprises at least one active ingredient.
10. The apparatus of claim 9, wherein the at least one active ingredient comprises insulin, GLP-1, growth hormone, sumatriptan, parathyroid hormone, or analogs thereof.
11. The apparatus of claim 6, wherein the first sensor is configured to transmit the signal by wire or wireless communication mode to the processing device.
12. The apparatus of claim 6, wherein an analog to digital converter communicates the signal to the microprocessor that is configured to analyze and process the signal.
13. The apparatus of claim 6, further comprising a signal conditioning circuitry and a wired or wireless communication interface.
14. The apparatus of claim 6, wherein data generated from the signal are processed by the microprocessor to generate a data set that recreates the patient's inhalation profile.
15. The apparatus of claim 6, wherein the first and second inhalers are structurally identical.
16. A method for simulating an inhalation maneuver by a subject, the method comprising: monitoring the inhalation maneuver by way of a first acoustic sensor located in or attached to a first breath-powered dry powder inhaler; transmitting a signal generated by the first acoustic sensor to a device comprising a microprocessor and a storage medium having an algorithm stored therein; processing the signal using the algorithm to generate a data set; and performing at least one of the following with the data set: storing the data set in the storage medium, transmitting the data set in the form of a second signal to a controller configured to control a motor that is attached to a calibrated syringe pump that upon actuation by the controller generates a pressure differential in a second breath-powered dry powder inhaler that is attached to an anatomically correct artificial airway, wherein the pressure differential is modeled after the inhalation maneuver.
17. The method of claim 16, wherein the airway is configured with a mouth connected to the second inhaler.
18. The method of claim 16, wherein the first inhaler is adapted with a radio transmitter.
19. The method of claim 16, wherein the first inhaler is adapted with a wireless or wired jacket comprising a microphone that can convert a sound signal generated within the first inhaler into an electrical impulse configured to communicate with a radio signal receiver that is in communication with the microprocessor.
20. The method of claim 16, wherein the first and second inhalers are structurally identical.
Read more: mnkd.proboards.com/thread/3166/mannkind-inhalation-simulation-system-patented#ixzz3kPfoaEZD
|
|
|
|
Post by mannmade on Aug 31, 2015 12:13:10 GMT -5
Google is also partnered with Dexcom for smaller less expensive CGM'S to be distributed directly at retail to consumers.
|
|
|
|
Post by nemzter on Aug 31, 2015 12:34:18 GMT -5
Sanofi partnered with Medtronic last year and we still have not heard of anything interesting out of that relationship.
Hopefully, this will move alot faster in letting us know what they may be up to ...
|
|
|
|
Post by Chris-C on Sept 1, 2015 14:10:22 GMT -5
IMO- any new development that creates real time and accessible state of the art glycemic digital monitoring will be helpful to Afrezza sales. An algorithm that tracks an individual's response to different doses of Afrezza over time and estimates unique cartridge requirements would play to Afrezza's strengths- assuming the potential liability issues could be overcome. At the least, non or minimally invasive real time (and continuous) glycemic monitoring would be huge! Google loves a digital challenge and has the firepower to do it. I predict that we will see this in our lifetimes (assuming we live another decade)!!!!
|
|
|
|
Post by dreamboatcruise on Sept 1, 2015 16:40:49 GMT -5
IMO- any new development that creates real time and accessible state of the art glycemic digital monitoring will be helpful to Afrezza sales. An algorithm that tracks an individual's response to different doses of Afrezza over time and estimates unique cartridge requirements would play to Afrezza's strengths- assuming the potential liability issues could be overcome. At the least, non or minimally invasive real time (and continuous) glycemic monitoring would be huge! Google loves a digital challenge and has the firepower to do it. I predict that we will see this in our lifetimes (assuming we live another decade)!!!! Such an algorithm would almost certainly have to go through numerous FDA approved clinical trials, just like an artificial pancreas would... likely with the assumption that a user follows the recommendations blindly. Software involving machine learning and AI are certainly getting to the point they could have many applications in health and medicine, but the current regulatory framework is holding many ideas back. |
|
|
|
Post by mnholdem on Sept 1, 2015 17:22:02 GMT -5
It's possible that Afrezza/Technosphere, once successful, will lead to a number of support industries. Could be anything...except syringes.
|
|
|
|
Post by esstan2001 on Sept 1, 2015 20:03:02 GMT -5
IMO- any new development that creates real time and accessible state of the art glycemic digital monitoring will be helpful to Afrezza sales. An algorithm that tracks an individual's response to different doses of Afrezza over time and estimates unique cartridge requirements would play to Afrezza's strengths- assuming the potential liability issues could be overcome. At the least, non or minimally invasive real time (and continuous) glycemic monitoring would be huge! Google loves a digital challenge and has the firepower to do it. I predict that we will see this in our lifetimes (assuming we live another decade)!!!! I heard the author of this report tonite on bloomberg radio; all the focus is on precise telemetry data uploaded to the cloud / patient warnings / Dr notifications, so correct dosing actions are taken, some 'neat tech' (i.e., blood-cell sized glucose sensors contained within contact lenses, bluetooth linked to a CGM, the ability to use realtime blood sugar data to adjust an insulin pump output)... What I came away with is they are very channeled into the current injected paradigm, how to finesse dosing, and keep your physician in the loop... There was no mention of afrezza. Sure, I can imagine adding bluetooth links to a sensor within the dreamboat that monitors delivered dose- that, through our ill equipped FDA, will be years away. And besides, one of Afrezza's key differentiators is how forgiving it is to inaccurate dosing beyond the insulin level required. So IMO, I think Afrezza is mostly a square peg as far as this initiative is concerned (BTW, Novartis and maybe one other are also part of it). But as to the part about monitoring blood sugar levels real time, and having the patient / doc know about it, yes that will be a big win for Afrezza- the sensing side will show it's superiority. Just don't see any automated way to close the loop; it will be your 'Dexcom' telling you what cartridge to take and when I guess. Sure wish Google would find some way to really integrate electronics tech with Afrezza... |
|
|
|
Post by mnholdem on Sept 1, 2015 22:35:37 GMT -5
Joslin partnering with Google, Sanofi to help disrupt diabetes
September 1, 2015 Jessica Bartlett, Reporter
Boston Business Journal
Joslin Diabetes Center will join in a collaboration with Google and Sanofi to develop new tools to manage and treat diabetes.
John Brooks, CEO of Joslin, said the companies already have an agreement in place, and will start more robust conversations in the next month to nail down the specifics of how tech giant Google (Nasdaq: GOOG), the French biotech Sanofi (NYSE: SNY) and Boston-based diabetes experts at Joslin will come together.
www.bizjournals.com/boston/blog/bioflash/2015/09/joslin-partnering-with-google-sanofi-to-help.html?ana=yahoo |
|
